Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 26, 2026.

The Gut and Parkinson's Disease—A Bidirectional Pathway

Susanne Fonseca Santos, Hadassa Loth de Oliveira, Elizabeth Sumi Yamada and 2 more

Frontiers in Neurology · 2019 · Review · CC BY

doi:10.3389/fneur.2019.00574

Abstract

Humans evolved a symbiotic relationship with their gut microbiome, a complex microbial community composed of bacteria, archaea, protists, and viruses, including bacteriophages. The enteric nervous system (ENS) is a gateway for the bidirectional communication between the brain and the gut, mostly through the vagus nerve (VN). Environmental exposure plays a pivotal role in both the composition and functionality of the gut microbiome and may contribute to susceptibility to neurodegenerative disorders, such as Parkinson's disease (PD). The neuropathological hallmark of PD is the widespread appearance of alpha-synuclein aggregates in both the central and peripheral nervous systems, including the ENS. Many studies suggest that gut toxins can induce the formation of α-syn aggregates in the ENS, which may then be transmitted in a prion-like manner to the CNS through the VN. PD is strongly associated with aging and its negative effects on homeostatic mechanisms protecting from inflammation, oxidative stress, and protein malfunction. In this mini-review, we revisit some landmark discoveries in the field of Parkinson's research and focus on the gut-brain axis. In the process, we highlight evidence showing gut-associated dysbiosis and related microbial-derived components as important players and risk factors for PD. Therefore, the gut microbiome emerges as a potential target for protective measures aiming to prevent PD onset.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 26, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Parkinson's Disease (PD) is a common neurodegenerative disorder typically associated with the progressive loss of dopaminergic neurons located in the midbrain nucleus substantia nigra pars compacta (SNpc). Although the cardinal symptoms of PD are motor impairments attributed to the depletion of the neurotransmitter dopamine in the striatum, a major target of the SNpc, it has been long recognized [for review, see] that other non-motor symptoms, including olfactory and gastrointestinal (GI) dysfunction, appear during the so-called premotor phase of the disease.

The neuropathological hallmark of PD is the presence of cytoplasmic inclusions, called Lewy bodies (LB) or Lewy neurites, in SNpc neurons. LBs are composed mostly of α-synuclein (α-syn) aggregates, whose aberrant soluble oligomeric conformations are thought to mediate its toxic effects. Alpha-syn is an intrinsically disordered protein (IDP), which lacks a stable 3D structure under physiological conditions and is characterized by exacerbated structural plasticity and conformational adaptability. As other IDPs possessing amyloidogenic regions, α-syn can turn into a promiscuous binder leading to abnormal interactions and the development of PD. Tuttle et al. provided a detailed 3D structure of functional α-syn fibrils (see Figure 1), using solid-state NMR spectroscopy. The study may serve as the basis for a better understanding of molecular mechanisms involved in α-syn fibril nucleation and propagation. In addition, such structural information may provide useful insights on possible interactions of α-synuclein with other proteins and small molecules and allow the emergence of new tools with potential to facilitate both the diagnosis and treatment of PD (e.g., imaging agents and therapeutic drugs).

Aggregates of α-syn fibrils are also found in neural tissue located outside the central nervous system (CNS) of PD patients, in both the autonomic and enteric nervous system (ENS), an outcome which may be associated with the non-motor symptoms of the disease [for review, see]. These findings led Braak et al. to propose a staging system for the progression of the disease following a specific pattern of α-syn aggregates spreading from peripheral toward more centralized locations in the brain. The triggering event would be the invasion of vulnerable neural structures such as the olfactory epithelium and the ENS, which interface directly with the external environment, by a neurotoxicant (“neurotropic virus”). While both structures possess immunological and physical barriers protecting them against environmental insults, these barriers steadily deteriorate with aging [for review, see], which is the biggest risk factor for idiopathic PD.

Animal studies have supported the claim that α-syn aggregates propagate in a prion-like manner [; for review, see] via microtubule-associated transport along axons. In summary, the prion hypothesis of PD proposes that amyloidogenic α-syn would induce a conformational change in the endogenous protein through permissive templating, convert it into a likeness of itself and propagate retrogradely through the vagus nerve or the olfactory tract from the ENS or the olfactory bulb, respectively. Even though definitive proof for this prion hypothesis is still missing and there is the controversial possibility that intestinal α-syn aggregates have a brain origin, it has been shown that vagotomy is associated with a decreased risk for PD in humans. Also, grafted neurons in PD patients develop α-syn aggregate pathology and α-syn from PD patients can cause nigrostriatal degeneration in mice and non-human primates. Remarkably, exogenous α-syn fibrils, either PD patient-derived or produced in E. coli, were able to seed the formation of LB-like inclusions which spread from the GI tract to the brain through the vagus nerve in rats.

Prior to Braak's hypothesis, however, there was already strong evidence pointing to the role played by exogenous toxins in the etiology of sporadic PD. For instance, postencephalitic parkinsonism (von Economo's disease), which has an autoimmune basis caused by a viral illness, is associated with degeneration of the basal ganglia. Additionally, the discovery of parkinsonism induced by 1-methyl-4-phenyl-1,2,4,5-tetrahydropyridine (MPTP) through self-administration, in 1982 brought to light a new class of xenobiotic substances that may cause PD-like symptoms by environmental contact. MPTP is a lipophilic compound which readily passes into the brain where it is converted by monoamine oxidase B (MAO-B) to 1-methyl-4-phenylpyridinium (MPP+) which is taken up by dopaminergic cells and impairs mitochondria respiration by poisoning complex 1. There are many heterocyclic molecules that structurally resemble MPTP and are found in the brain from both endogenous and exogenous sources, such as tetrahydroisoquinolines (TIQ) and β-carbolines (β-C). For instance, a TIQ derivative, salsolinol, which is produced by enterobacteria and has been found in the urine of PD patients, may have a double-faced, dose-dependent effect on the nigrostriatal pathway as either a harmful or protective agent.

The evidence for the role played by toxins in inducing parkinsonism and the relative scarcity of familial cases (about 10%) underscore the importance of environmental and lifestyle factors over genetic ones in the etiology of the disease. Some chronic diseases have been associated with a phenomenon called evolutionary mismatch when ancestral traits are no longer adaptive in modern contexts. For instance, α-syn is involved with normal synaptic function by regulating, among other things, the size of presynaptic vesicles and the assembly of SNARE proteins involved with the docking of synaptic vesicles to presynaptic membranes. However, as old age became common in humans after the early upper Paleolithic, the steady increase in longevity seen in modern times may have had a collateral effect on the protein homeostasis (proteostasis) network, which coordinates protein synthesis, folding, trafficking, disaggregation, and degradation. The breakdown of proteostasis, which is a common feature of many neurodegenerative diseases, means that misfolded proteins may accumulate due to lack of clearance or failure to refold into their native structures. In the case of prion-like proteins, this may cause further protein misfolding (template effect) leading to protein aggregation and ultimately cell death.

The Gut-Brain Axis and Parkinson's Disease

The gut-brain axis is mediated by intense bidirectional communication between the CNS and the ENS. Through the ENS, the gut microbiota influences the development and function of all divisions of the nervous system and this association was established very early during the evolution of multicellular organisms. The first nervous system appeared more than 500 million years ago before the divergence of cnidarians and bilaterians, the two metazoan sister groups. That primitive brain had a simple structure, organized as a diffuse nerve net which controlled a restricted set of basic behaviors and was the template for the subsequent evolution of the mammalian ENS, which retained many of its basic structural characteristics, such as a network of nervous ganglia distributed in the myenteric and submucous plexuses. Higher vertebrates went to evolve an additional set of neural structures in the central nervous system (CNS), tasked with the control of more sophisticated behaviors. However, the ENS and the CNS maintain intense crosstalk through reciprocal connections mediated by the VN (Figure 1) and pelvic nerve in mammals. As the main substrate for this information exchange, the vagus nerve is an attractive target of neurostimulation therapies for the treatment of psychiatric and gastrointestinal disorders.

The GI tract harbors a complex microbial ecosystem (Figure 1), consisting of bacteria, archaea, protists, and eukaryotic and prokaryotic viruses, also known as bacteriophages. The human microbiome has coevolved with its host, which keeps a tight leash on the intrinsic competitive nature of the microorganisms that comprise the microbiome, through both the nervous and the immune systems. This arrangement maximizes the benefits the host gains from the symbiotic relationship, including protection against pathogens, improved nutrition, and mental health. A sub-type of intestinal epithelial cells called enteroendocrine cells, provide a signaling pathway through which the microbiome interacts with the CNS via the vagus nerve. Enteroendocrine cells have diverse phenotypes and express a variety of peptides/hormones that can act as signaling molecules on distinct targets, both local and distant, and some are chemoreceptors responding to a variety of luminal stimuli. As other intestinal epithelial cells, enteroendocrine cells express toll-like receptors, allowing them to detect bacterial products, and activate vagal afferents through basal processes called neuropods (see Figure 1).

The Gut Microbiome and Brain Function

There is increasing evidence of the association between microbiome dysfunction and CNS-related co-morbidities, such as anxiety, depression, autism spectrum disorders, Alzheimer's disease and PD. This association probably arose as a by-product of natural selection forces acting on microorganisms to adapt to the host and vice-versa. The effect of the microbiota on the CNS can lead to behavior modifications and even to host manipulation associated with increasing fitness of its bacterial populations. For instance, the microbiome can influence social interactions by acting on the nutritional behavior of individual animals, particularly those from social species where individuals share microbes and interact around foods. The proximate neuro-endocrinological and inflammatory mechanisms underlying this type of host manipulation are largely shared by the microbiome and the host. For instance, levels of many neurotransmitters that are important for the expression of social behavior, such as serotonin (5-HT), dopamine, norepinephrine (NE), γ-aminobutyric acid (GABA), and glutamate are either expressed or regulated by bacteria. Particularly, most of the body's serotonin (5-HT) (5-hydroxytryptamine) is produced in the gut by enterochromaffin cells (EC) under the influence of the microbiome. The activation of 5-HT4 receptors induces the maturation of the ENS and regulates its adult function. In the gut, there are three major metabolic pathways leading from the essential amino acid tryptophan (Trp) to 5-HT, kynurenine (Kyn), and indole derivatives, which are under the direct or indirect control of the microbiota. During inflammatory states, most tryptophan is diverted to the production of Kyn and its metabolites kynurenine acid (KYNA) and quinolinic acid (QUIN). While KYNA is considered neuroprotective, QUIN can cause excitotoxicity as an agonist of N-methyl-d-aspartate (NMDA) receptor and contribute to the neuropathogenesis of PD [for review, see].

Although α-syn aggregates are also seen in the ENS of normally aging subjects, especially in the appendix, it is more prevalent in PD patients. Recent in vivo models showed that accumulation of α-syn aggregates in the ENS can be induced by alterations in the gut microbiome. Interestingly, Sampson et al. demonstrated in mice, genetically modified to overexpress α-syn, that the presence of gut microbiota is necessary to promote pathological alterations and motor deficits similar to PD. They also demonstrated that fecal transplants from PD patients impair motor function in the same mouse strain, strongly suggesting that gut microbes may play a pivotal role in the onset of synucleinopathies such as PD. Underlying these findings is the fact that microbial amyloids produced by some members of the gut microbiota can be released in the extracellular space, where they can be internalized by neighboring cells, including neurons, and seed the formation of pathological aggregates of endogenous α-syn through permissive templating. The failure of normal clearance mechanisms such as the ubiquitin-proteasome system, characteristic of both familial and idiopathic PD, to degrade the misfolded protein, may facilitate the seeding process.

The concept of microbial dysbiosis also comprises the bacteriophage components of the microbiome. Bacteriophages (phages) are viral parasites of bacteria and are important regulators of host-microbiome interactions through horizontal gene transfer and antagonistic coevolution. Besides targeting bacteria, phages can impact human health by playing a direct role on intestinal inflammatory processes and possibly causing α-syn misfolding. A recent study showed significant differences in the gut phagobiota of PD patients and healthy individuals and a depletion of Lactococcus bacteria in the former, which is associated with the regulation of gut permeability and dopamine production, two factors linked with the early signs of PD in the gut. Phage therapy has recently returned to the spotlight as an alternative antimicrobial strategy. Eventually, it may also contribute to fighting PD through targeted approaches to manipulate the microbiome.

Probiotic bacteria have been linked to improved GI symptoms associated with PD. Probiotics affect the functionality of the CNS through beneficial interactions with the commensal gut microbiota and modulation of gut-derived inflammation. The microbiota of PD patients exhibits a pro-inflammatory profile due to increased intestinal permeability to endotoxins (lipopolysaccharide). Bacterial amyloids may also favor a pro-inflammatory environment in the gut. A common bacterial component, the Curli fimbriae, share structural and biophysical properties with amyloids and are produced by E. coli through coordinated biosynthetic processes. Other components of the gut microbiome are also known to produce functional extracellular amyloids [e.g., Salmonella, Klebsiella, Citrobacter, and Bacillus species;]. Since probiotic treatment induces an anti-inflammatory peripheral immune response in multiple sclerosis patients there is a possibility they may also be beneficial for PD patients, although there are no reports corroborating this hypothesis. One option is to take advantage of Lactobacilli's ability to inhibit the formation of biofilms by pathogenic bacteria. One caveat, however, is that the effects of probiotics are highly variable, being person-specific, as shown in a recent study. This limitation may be counteracted with the use of genetically-modified probiotics able to deliver novel therapeutics efficiently and with site specificity. Despite the increasing number of probiotic products available to consumers and the aggressive marketing proclaiming their efficacy, there have been few studies addressing concerns about efficacy and, more importantly, the safety of these products. There is an urgent need for more studies about the therapeutic potential of specific bacterial strains to help maintain oxidative and protein homeostasis in the ENS.

Concluding Remarks

Aging is the main risk factor for the development of PD and delaying the aging process is neuroprotective to PD in animal models. Aging is also associated with the accumulation of neuroinflammatory sequelae and the breakdown of homeostatic mechanisms that protect against protein misfolding, oxidative stress, decreased mitochondrial function, etc. The gut, as one of the main gateways to environmental exposure to the brain, may contribute to increasing the susceptibility to these factors. The microbiome has a protective effect mediating this exposure, and dysbiosis seems to be a pivotal risk factor for PD and other neurological disorders. Thus, the adoption of preventive measures to ensure a healthy microbiome throughout the lifetime can potentially decrease the risk of developing PD and other neurodegenerative diseases. The widespread use of antibiotics, for instance, which can kill gut bacteria indiscriminately, can cause a shift of the microbiome to an alternative stable state with unknown consequences in the long term.

Author Contributions

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 142

  1. 1.

    Dauer W Przedborski S. Parkinson's disease: mechanisms and models. Neuron. (2003 ) 39:889–909.

    Not in our library10.1016/s0896-6273(03)00568-3

  2. 2.

    Hughes AJ Daniel SE Kilford L Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. (1992 ) 55:181–4.

    Not in our library10.1136/jnnp.55.3.181

  3. 3.

    Garcia-Ruiz PJ Chaudhuri KR Martinez-Martin P. Non-motor symptoms of Parkinson's disease A review…from the past. J Neurol Sci. (2014 ) 338:30–3.

    Not in our library10.1016/j.jns.2014.01.002

  4. 4.

    Braak H Rüb U Gai WP Del Tredici K. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm. (2003 ) 110:517–36.

    Not in our library10.1007/s00702-002-0808-2

  5. 5.

    Doty RL Deems DA Stellar S Olfactory dysfunction in parkinsonism A general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology. (1988 ) 38:1237–1237.

    Not in our library10.1212/wnl.38.8.1237

  6. 6.

    Pearce RK Hawkes CH Daniel SE. The anterior olfactory nucleus in Parkinson's disease. Mov Disord. (1995 ) 10:283–7.

    Not in our library10.1002/mds.870100309

  7. 7.

    Lewy F Paralysis agitans pathologische anatomie. In: Lewandowski M editor. Handbuch der Neurologie. Berlin: Springer (1912 ). p. 920–33.

    Not in our library

  8. 8.

    Okazaki H Lipkin LE Aronson SM. Diffuse intracytoplasmic ganglionic inclusions (Lewy type) associated with progressive dementia and quadriparesis in flexion. J Neuropathol Exp Neurol. (1961 ) 20:237–44.

    Not in our library10.1097/00005072-196104000-00007

  9. 9.

    Polymeropoulos MH Lavedan C Leroy E Ide SE Dehejia A Dutra A. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science. (1997 ) 276:2045–7.

    Not in our library10.1126/science.276.5321.2045

  10. 10.

    Gibb WR Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. (1988 ) 51:745–52.

    Not in our library10.1136/jnnp.51.6.745

  11. 11.

    Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci. (2001 ) 2:492–501.

    Not in our library10.1038/35081564

  12. 12.

    Gründemann J Schlaudraff F Haeckel O Liss B. Elevated α-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease. Nucleic Acids Res. (2008 ) 36:e38.

    Not in our library10.1093/nar/gkn084

  13. 13.

    Spillantini MG Crowther RA Jakes R Hasegawa M Goedert M. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA. (1998 ) 95:6469–73.

    Not in our library10.1073/pnas.95.11.6469

  14. 14.

    Stefanis L. α-Synuclein in Parkinson's disease. Cold Spring Harb Perspect Med. (2012 ) 2:a009399.

    Not in our library10.1101/cshperspect.a009399

  15. 15.

    Uversky VN Dunker AK. Understanding protein non-folding. Biochim Biophys Acta BBA Proteins Proteomics. (2010 ) 1804:1231–64.

    Not in our library10.1016/j.bbapap.2010.01.017

  16. 16.

    Esteras-Chopo A Serrano L López de la Paz M. The amyloid stretch hypothesis: recruiting proteins toward the dark side. Proc Natl Acad Sci USA. (2005 ) 102:16672–7.

    Not in our library10.1073/pnas.0505905102

  17. 17.

    Uversky VN. Wrecked regulation of intrinsically disordered proteins in diseases: pathogenicity of deregulated regulators. Front Mol Biosci. (2014 ) 1:6.

    Not in our library10.3389/fmolb.2014.00006

  18. 18.

    Tuttle MD Comellas G Nieuwkoop AJ Covell DJ Berthold DA Kloepper KD. Solid-state NMR structure of a pathogenic fibril of full-length human α-synuclein. Nat Struct Mol Biol. (2016 ) 23:409–15.

    Not in our library10.1038/nsmb.3194

  19. 19.

    Rose AS Bradley AR Valasatava Y Duarte JM Prlic A Rose PW. NGL viewer: web-based molecular graphics for large complexes. Bioinforma. (2018 ) 34:3755–8.

    Not in our library10.1093/bioinformatics/bty419

  20. 20.

    Kaelberer MM Buchanan KL Klein ME Barth BB Montoya MM Shen X. A gut-brain neural circuit for nutrient sensory transduction. Science. (2018 ) 361:eaat5236.

    Not in our library10.1126/science.aat5236

  21. 21.

    Bohórquez DV Shahid RA Erdmann A Kreger AM Wang Y Calakos N. Neuroepithelial circuit formed by innervation of sensory enteroendocrine cells. J Clin Invest. (2015 ) 125:782–6.

    Not in our library10.1172/jci78361

  22. 22.

    Anselmi L Bove C Coleman FH Le K Subramanian MP Venkiteswaran K. Ingestion of subthreshold doses of environmental toxins induces ascending Parkinsonism in the rat. NPJ Parkinson Dis. (2018 ) 4:30.

    Not in our library10.1038/s41531-018-0066-0

  23. 23.

    Hawkes CH Del Tredici K Braak H. Parkinson's disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol. (2007 ) 33:599–614.

    Not in our library10.1111/j.1365-2990.2007.00874.x

  24. 24.

    Gershon MD Bursztajn S. Properties of the enteric nervous system: limitation of access of intravascular macromolecules to the myenteric plexus and muscularis externa. J Comp Neurol. (1978 ) 180:467–88.

    Not in our library10.1002/cne.901800305

  25. 25.

    Mellert TK Getchell ML Sparks L Getchell TV. Characterization of the immune barrier in human olfactory mucosa. Otolaryngol Head Neck Surg. (1992 ) 106:181–8.

    Not in our library

  26. 26.

    Attems J Walker L Jellinger KA. Olfaction and aging: a mini-review. Gerontology. (2015 ) 61:485–90.

    Not in our library10.1159/000381619

  27. 27.

    Bowman GL Dayon L Kirkland R Wojcik J Peyratout G Severin IC. Blood-brain barrier breakdown, neuroinflammation, and cognitive decline in older adults. Alzheimer Dement. (2018 ) 14:1640–50.

    Not in our library10.1016/j.jalz.2018.06.2857

  28. 28.
    Ageing and Parkinson's disease: Why is advancing age the biggest risk factor? · 2014
    No notice
  29. 29.
    Rapid dissemination of alpha-synuclein seeds through neural circuits in an in-vivo prion-like seeding experiment · 2018
    Not checked
  30. 30.

    Steiner JA Quansah E Brundin P. The concept of alpha-synuclein as a prion-like protein: ten years after. Cell Tissue Res. (2018 ) 373:161–73.

    Not in our library10.1007/s00441-018-2814-1

  31. 31.

    Holmqvist S Chutna O Bousset L Aldrin-Kirk P Li W Björklund T. Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathol. (2014 ) 128:805–20.

    Not in our library10.1007/s00401-014-1343-6

  32. 32.

    Eisenberg D Jucker M. The amyloid state of proteins in human diseases. Cell. (2012 ) 148:1188–203.

    Not in our library10.1016/j.cell.2012.02.022

  33. 33.

    Stopschinski BE Diamond MI. The prion model for progression and diversity of neurodegenerative diseases. Lancet Neurol. (2017 ) 16:323–32.

    Not in our library10.1016/s1474-4422(17)30037-6

  34. 34.

    Lawson VA Furness JB Klemm HM Pontell L Chan E Hill AF. The brain to gut pathway: a possible route of prion transmission. Gut. (2010 ) 59:1643–51.

    Not in our library10.1136/gut.2010.222620

  35. 35.

    Ulusoy A Phillips RJ Helwig M Klinkenberg M Powley TL Di Monte DA. Brain-to-stomach transfer of α-synuclein via vagal preganglionic projections. Acta Neuropathol. (2017 ) 133:381–93.

    Not in our library10.1007/s00401-016-1661-y

  36. 36.

    Liu B Fang F Pedersen NL Tillander A Ludvigsson JF Ekbom A. Vagotomy and Parkinson disease: a Swedish register-based matched-cohort study. Neurology. (2017a ) 88:1996–2002.

    Not in our library10.1212/wnl.0000000000003961

  37. 37.

    Svensson E Horváth-Puhó E Thomsen RW Djurhuus JC Pedersen L Borghammer P. Vagotomy and subsequent risk of Parkinson's disease. Ann Neurol. (2015 ) 78:522–9.

    Not in our library10.1002/ana.24448

  38. 38.

    Kordower JH Chu Y Hauser RA Freeman TB Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med. (2008a ) 14:504–6.

    Not in our library10.1038/nm1747

  39. 39.

    Kordower JH Chu Y Hauser RA Olanow CW Freeman TB. Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov Disord. (2008b ) 23:2303–6.

    Not in our library10.1002/mds.22369

  40. 40.

    Li J-Y Englund E Holton JL Soulet D Hagell P Lees AJ. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med. (2008 ) 14:501–3.

    Not in our library10.1038/nm1746

  41. 41.

    Recasens A Dehay B Bové J Carballo-Carbajal I Dovero S Pérez-Villalba A. Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol. (2014 ) 75:351–62.

    Not in our library10.1002/ana.24066

  42. 42.

    Jang H Boltz DA Webster RG Smeyne RJ. Viral parkinsonism. Biochim Biophys Acta. (2009 ) 1792:714–21.

    Not in our library10.1016/j.bbadis.2008.08.001

  43. 43.

    von Economo C Encephalitis lethargica: its sequelae and treatment. JAMA. (1931 ) 98:255

    Not in our library10.1001/jama.1932.02730290071039

  44. 44.

    Langston JW. The MPTP story. J Parkinson Dis. (2017 ) 7:S11–S19.

    Not in our library10.3233/jpd-179006

  45. 45.

    Chiba K Trevor A Castagnoli N. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun. (1984 ) 120:574–8.

    Not in our library10.1016/0006-291x(84)91293-2

  46. 46.

    Javitch JA D'Amato RJ Strittmatter SM Snyder SH. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA. (1985 ) 82:2173–7.

    Not in our library10.1073/pnas.82.7.2173

  47. 47.
    Production of the Neurotoxin Salsolinol by a Gut-Associated Bacterium and Its Modulation by Alcohol · 2018
    Not checked
  48. 48.

    Kurnik-Łucka M Panula P Bugajski A Gil K. Salsolinol: an unintelligible and double-faced molecule—lessons learned from in vivo and in vitro experiments. Neurotox Res. (2018 ) 33:485–514.

    Not in our library10.1007/s12640-017-9818-6

  49. 49.

    Thomas B Beal MF Parkinson's disease. Hum Mol Genet. (2007 ) 16:R183–94.

    Not in our library10.1093/hmg/ddm159

  50. 50.

    Garcia-Ruiz PJ Espay AJ. Parkinson disease: an evolutionary perspective. Front Neurol. (2017 ) 8:157.

    Not in our library10.3389/fneur.2017.00157

  51. 51.

    Jomova K Vondrakova D Lawson M Valko M. Metals, oxidative stress and neurodegenerative disorders. Mol Cell Biochem. (2010 ) 345:91–104.

    Not in our library10.1007/s11010-010-0563-x

  52. 52.

    Kalinderi K Bostantjopoulou S Fidani L. The genetic background of Parkinson's disease: current progress and future prospects. Acta Neurol Scand. (2016 ) 134:314–26.

    Not in our library10.1111/ane.12563

  53. 53.

    Gluckman PD Hanson MA. Living with the past: evolution, development, and patterns of disease. Science. (2004 ) 305:1733–6.

    Not in our library10.1126/science.1095292

  54. 54.

    Tooby J Cosmides L The past explains the present: emotional adaptations and the structure of ancestral environments. Ethol Sociobiol. (1990 ) 11:375–424.

    Not in our library

  55. 55.

    Murphy DD Rueter SM Trojanowski JQ Lee VM. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci. (2000 ) 20:3214–20.

    Not in our library10.1523/jneurosci.20-09-03214.2000

  56. 56.

    Burré J Sharma M Tsetsenis T Buchman V Etherton MR Südhof TC. Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science. (2010 ) 329:1663–7.

    Not in our library10.1126/science.1195227

  57. 57.

    Caspari R Lee S-H. Older age becomes common late in human evolution. Proc Natl Acad Sci USA. (2004 ) 101:10895–900.

    Not in our library10.1073/pnas.0402857101

  58. 58.

    Kaushik S Cuervo AM. Proteostasis and aging. Nat Med. (2015 ) 21:1406–15.

    Not in our library10.1038/nm.4001

  59. 59.

    Powers ET Morimoto RI Dillin A Kelly JW Balch WE. Biological and chemical approaches to diseases of proteostasis deficiency. Annu Rev Biochem. (2009 ) 78:959–91.

    Not in our library10.1146/annurev.biochem.052308.114844

  60. 60.

    Balch WE Morimoto RI Dillin A Kelly JW. Adapting proteostasis for disease intervention. Science. (2008 ) 319:916–9.

    Not in our library10.1126/science.1141448

  61. 61.

    Kikis EA Gidalevitz T Morimoto RI. Protein homeostasis in models of aging and age-related conformational disease. In: Tavernarakis N. editor. Protein Metabolism and Homeostasis in Aging Advances in Experimental Medicine and Biology. Boston, MA: Springer (2010 ). p. 138–59.

    Not in our library10.1007/978-1-4419-7002-2_11

  62. 62.

    Bobela W Aebischer P Schneider BL Alpha-synuclein as a mediator in the interplay between aging and Parkinson's disease. Biomolecules. (2015 ) 5:2675–700.

    Not in our library10.3390/biom5042675

  63. 63.

    Carabotti M Scirocco A Maselli MA Severi C. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol Q Publ Hell Soc Gastroenterol. (2015 ) 28:203–9.

    Not in our library

  64. 64.

    Diaz Heijtz R Wang S Anuar F Qian Y Bjorkholm B Samuelsson A. Normal gut microbiota modulates brain development and behavior. Proc Natl Acad Sci USA. (2011 ) 108:3047–52.

    Not in our library10.1073/pnas.1010529108

  65. 65.

    Kelava I Rentzsch F Technau U. Evolution of eumetazoan nervous systems: insights from cnidarians. Philos Trans R Soc B Biol Sci. (2015 ) 370:20150065.

    Not in our library10.1098/rstb.2015.0065

  66. 66.

    Furness JB Stebbing MJ. The first brain: species comparisons and evolutionary implications for the enteric and central nervous systems. Neurogastroenterol Motil. (2018 ) 30:13234.

    Not in our library10.1111/nmo.13234

  67. 67.

    Koizumi O Origin and evolution of the nervous system considered from the diffuse nervous system of cnidarians. In: Goffredo S Dubinsky Z editors. The Cnidaria, Past, Present and Future: The World of Medusa and Her Sisters. Cham: Springer International Publishing (2016 ). p. 73–91.

    Not in our library

  68. 68.

    Shimizu H Koizumi O Fujisawa T. Three digestive movements in Hydra regulated by the diffuse nerve net in the body column. J Comp Physiol A Neuroethol Sens Neural Behav Physiol. (2004 ) 190:623–30.

    Not in our library10.1007/s00359-004-0518-3

  69. 69.

    Costa M Brookes SJH Hennig GW. Anatomy and physiology of the enteric nervous system. Gut. (2000 ) 47:iv15–9.

    Not in our library10.1136/gut.47.suppl_4.iv15

  70. 70.

    Kaas J Evolution of Nervous Systems. 2nd ed. Academic Press (2017 ). Available online at: https://www.sciencedirect.com/referencework/9780128040966/evolution-of-nervous-systems (accessed April 6, 2019).

    Not in our library

  71. 71.

    Powell N Walker MM Talley NJ. The mucosal immune system: master regulator of bidirectional gut-brain communications. Nat Rev Gastroenterol Hepatol. (2017 ) 14:143–59.

    Not in our library10.1038/nrgastro.2016.191

  72. 72.

    Rao M Gershon MD. The bowel and beyond: the enteric nervous system in neurological disorders. Nat Rev Gastroenterol Hepatol. (2016 ) 13:517–28.

    Not in our library10.1038/nrgastro.2016.107

  73. 73.
    Vagus Nerve as Modulator of the Brain–Gut Axis in Psychiatric and Inflammatory Disorders · 2018
    No notice
  74. 74.

    Johnson RL Wilson CG. A review of vagus nerve stimulation as a therapeutic intervention. J Inflamm Res. (2018 ) 11:203–13.

    Not in our library10.2147/jir.s163248

  75. 75.

    Gerritsen J Smidt H Rijkers GT de Vos WM. Intestinal microbiota in human health and disease: the impact of probiotics. Genes Nutr. (2011 ) 6:209–40.

    Not in our library10.1007/s12263-011-0229-7

  76. 76.

    Ley RE Lozupone CA Hamady M Knight R Gordon JI. Worlds within worlds: evolution of the vertebrate gut microbiota. Nat Rev Microbiol. (2008 ) 6:776–88.

    Not in our library10.1038/nrmicro1978

  77. 77.

    Selber-Hnatiw S Rukundo B Ahmadi M Akoubi H Al-Bizri H Aliu AF. Human gut microbiota: toward an ecology of disease. Front Microbiol. (2017 ) 8:1265.

    Not in our library10.3389/fmicb.2017.01265

  78. 78.

    Moeller AH Caro-Quintero A Mjungu D Georgiev AV Lonsdorf EV Muller MN. Cospeciation of gut microbiota with hominids. Science. (2016 ) 353:380–2.

    Not in our library10.1126/science.aaf3951

  79. 79.

    Bailey MT Dowd SE Galley JD Hufnagle AR Allen RG Lyte M. Exposure to a social stressor alters the structure of the intestinal microbiota: implications for stressor-induced immunomodulation. Brain Behav Immun. (2011 ) 25:397–407.

    Not in our library10.1016/j.bbi.2010.10.023

  80. 80.
    Exposure to a social stressor disrupts the community structure of the colonic mucosa-associated microbiota · 2014
    No notice
  81. 81.

    Foster KR Schluter J Coyte KZ Rakoff-Nahoum S. The evolution of the host microbiome as an ecosystem on a leash. Nature. (2017 ) 548:43–51.

    Not in our library10.1038/nature23292

  82. 82.

    Zilber-Rosenberg I Rosenberg E. Role of microorganisms in the evolution of animals and plants: the hologenome theory of evolution. FEMS Microbiol Rev. (2008 ) 32:723–35.

    Not in our library10.1111/j.1574-6976.2008.00123.x

  83. 83.

    Hoffman BU Lumpkin EA. A gut feeling. Science. (2018 ) 361:1203–4.

    Not in our library10.1126/science.aau9973

  84. 84.

    Feher J 8.3—Intestinal and colonic chemoreception and motility. In: Feher J editor. Quantitative Human Physiology, 2nd Edn. Boston: Academic Press (2017 ). p. 796–809.

    Not in our library

  85. 85.

    Latorre R Sternini C De Giorgio R Greenwood-Van Meerveld B. Enteroendocrine cells: a review of their role in brain-gut communication. Neurogastroenterol Motil. (2016 ) 28:620–30.

    Not in our library10.1111/nmo.12754

  86. 86.

    Bogunovic M Davé SH Tilstra JS Chang DTW Harpaz N Xiong H. Enteroendocrine cells express functional Toll-like receptors. Am J Physiol Gastrointest Liver Physiol. (2007 ) 292:G1770–1783.

    Not in our library10.1152/ajpgi.00249.2006

  87. 87.
    NeuropodsSummary · 2019
    Not checked
  88. 88.

    Dinan TG Cryan JF Gut feelings on ParkinsonŠs and depression. Cerebrum. (2017 ) 2017:cer-04-17.

    Not in our library

  89. 89.

    Hsiao EY McBride SW Hsien S Sharon G Hyde ER McCue T. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell. (2013 ) 155:1451–63.

    Not in our library10.1016/j.cell.2013.11.024

  90. 90.
    Cross Talk: The Microbiota and Neurodevelopmental Disorders · 2017
    No notice
  91. 91.

    Pellegrini C Antonioli L Colucci R Blandizzi C Fornai M. Interplay among gut microbiota, intestinal mucosal barrier and enteric neuro-immune system: a common path to neurodegenerative diseases? Acta Neuropathol. (2018 ) 136:345–61.

    Not in our library10.1007/s00401-018-1856-5

  92. 92.

    Unger MM Spiegel J Dillmann K-U Grundmann D Philippeit H Bürmann J. Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls. Parkinson Relat Disord. (2016 ) 32:66–72.

    Not in our library10.1016/j.parkreldis.2016.08.019

  93. 93.

    Johnson KV-A Foster KR. Why does the microbiome affect behaviour? Nat Rev Microbiol. (2018 ) 16:647–55.

    Not in our library10.1038/s41579-018-0014-3

  94. 94.

    Akami M Andongma AA Zhengzhong C Nan J Khaeso K Jurkevitch E. Intestinal bacteria modulate the foraging behavior of the oriental fruit fly Bactrocera dorsalis (Diptera: Tephritidae). PLoS ONE. (2019 ) 14:e0210109.

    Not in our library10.1371/journal.pone.0210109

  95. 95.

    Schretter CE Vielmetter J Bartos I Marka Z Marka S Argade S. A gut microbial factor modulates locomotor behaviour in Drosophila. Nature. (2018 ) 563:402.

    Not in our library10.1038/s41586-018-0634-9

  96. 96.
    Microbes can help explain the evolution of host altruism · 2017
    Not checked
  97. 97.

    Pasquaretta C Gómez-Moracho T Heeb P Lihoreau M. Exploring interactions between the gut microbiota and social behavior through nutrition. Genes. (2018 ) 9:E534.

    Not in our library10.3390/genes9110534

  98. 98.

    Freestone P. Communication between bacteria and their hosts. Scientifica. (2013 ) 2013:361073.

    Not in our library10.1155/2013/361073

  99. 99.
    The Neuro-endocrinological Role of Microbial Glutamate and GABA Signaling · 2016
    No notice
  100. 100.

    Liu R Hong J Xu X Feng Q Zhang D Gu Y. Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention. Nat Med. (2017b ) 23:859–68.

    Not in our library10.1038/nm.4358

  101. 101.

    Strandwitz P Kim KH Terekhova D Liu JK Sharma A Levering J. GABA-modulating bacteria of the human gut microbiota. Nat Microbiol. (2019 ) 4:396.

    Not in our library10.1038/s41564-018-0307-3

  102. 102.

    Vodolazov IR Dbar SD Oleskin AV Stoyanova LG Exogenous and endogenous neuroactive biogenic amines: studies with Lactococcus lactis subsp. lactis Appl Biochem Microbiol. (2018 ) 54:603–10.

    Not in our library10.1134/s0003683818060157

  103. 103.

    Yano JM Yu K Donaldson GP Shastri GG Ann P Ma L. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell. (2015 ) 161:264–76.

    Not in our library10.1016/j.cell.2015.02.047

  104. 104.

    Vadder FD Grasset E Holm LM Karsenty G Macpherson AJ Olofsson LE. Gut microbiota regulates maturation of the adult enteric nervous system via enteric serotonin networks. Proc Natl Acad Sci USA. (2018 ) 115:6458–63.

    Not in our library10.1073/pnas.1720017115

  105. 105.

    Agus A Planchais J Sokol H. Gut microbiota regulation of tryptophan metabolism in health and disease. Cell Host Microbe. (2018 ) 23:716–24.

    Not in our library10.1016/j.chom.2018.05.003

  106. 106.

    Keszthelyi D Troost FJ Jonkers DM van Donkelaar EL Dekker J Buurman WA. Does acute tryptophan depletion affect peripheral serotonin metabolism in the intestine? Am J Clin Nutr. (2012 ) 95:603–8.

    Not in our library10.3945/ajcn.111.028589

  107. 107.

    Lim CK Fernández-Gomez FJ Braidy N Estrada C Costa C Costa S. Involvement of the kynurenine pathway in the pathogenesis of Parkinson's disease. Prog Neurobiol. (2017 ) 155:76–95.

    Not in our library10.1016/j.pneurobio.2015.12.009

  108. 108.

    Böttner M Zorenkov D Hellwig I Barrenschee M Harde J Fricke T. Expression pattern and localization of alpha-synuclein in the human enteric nervous system. Neurobiol Dis. (2012 ) 48:474–80.

    Not in our library10.1016/j.nbd.2012.07.018

  109. 109.

    Gray MT Munoz DG Gray DA Schlossmacher MG Woulfe JM. Alpha-synuclein in the appendiceal mucosa of neurologically intact subjects. Mov Disord. (2014 ) 29:991–8.

    Not in our library10.1002/mds.25779

  110. 110.

    Barrenschee M Zorenkov D Böttner M Lange C Cossais F Scharf AB. Distinct pattern of enteric phospho-alpha-synuclein aggregates and gene expression profiles in patients with Parkinson's disease. Acta Neuropathol Commun. (2017 ) 5:1.

    Not in our library10.1186/s40478-016-0408-2

  111. 111.
    Exposure to the Functional Bacterial Amyloid Protein Curli Enhances Alpha-Synuclein Aggregation in Aged Fischer 344 Rats and Caenorhabditis elegans · 2016
    No notice
  112. 112.

    Sampson TR Debelius JW Thron T Janssen S Shastri GG Ilhan ZE. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease. Cell. (2016 ) 167:1469–80.e12.

    Not in our library10.1016/j.cell.2016.11.018

  113. 113.
    The role of microbial amyloid in neurodegeneration · 2017
    No notice
  114. 114.

    Soto C Pritzkow S. Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases. Nat Neurosci. (2018 ) 21:1332–40.

    Not in our library10.1038/s41593-018-0235-9

  115. 115.

    McNaught KSP Olanow CW Halliwell B Isacson O Jenner P. Failure of the ubiquitin–proteasome system in Parkinson's disease. Nat Rev Neurosci. (2001 ) 2:589–94.

    Not in our library10.1038/35086067

  116. 116.
    The Human Gut Phage Community and Its Implications for Health and Disease · 2017
    No notice
  117. 117.

    Duerkop BA. Bacteriophages shift the focus of the mammalian microbiota. PLoS Pathog. (2018 ) 14:e1007310.

    Not in our library10.1371/journal.ppat.1007310

  118. 118.

    Scanlan PD. Bacteria–bacteriophage coevolution in the human gut: implications for microbial diversity and functionality. Trends Microbiol. (2017 ) 25:614–23.

    Not in our library10.1016/j.tim.2017.02.012

  119. 119.

    Gogokhia L Buhrke K Bell R Hoffman B Brown DG Hanke-Gogokhia C. Expansion of bacteriophages is linked to aggravated intestinal inflammation and colitis. Cell Host Microbe. (2019 ) 25:285–99.e8.

    Not in our library10.1016/j.chom.2019.01.008

  120. 120.

    Tetz G Tetz V Tetz G Tetz V. Bacteriophages as new human viral pathogens. Microorganisms. (2018b ) 6:54.

    Not in our library10.3390/microorganisms6020054

  121. 121.
    Parkinson’s disease and bacteriophages as its overlooked contributors · 2018
    Corrected
  122. 122.

    Darby TM Owens JA Saeedi BJ Luo L Matthews JD Robinson BS. Lactococcus lactis subsp. cremoris is an efficacious beneficial bacterium that limits tissue injury in the intestine iScience. (2019 ) 12:356–67.

    Not in our library10.1016/j.isci.2019.01.030

  123. 123.
    The gut-brain axis: is intestinal inflammation a silent driver of Parkinson’s disease pathogenesis? · 2017
    No notice
  124. 124.

    Chan BK Abedon ST Loc-Carrillo C. Phage cocktails and the future of phage therapy. Future Microbiol. (2013 ) 8:769–83.

    Not in our library10.2217/fmb.13.47

  125. 125.
    Phage Therapy: Combating Infections with Potential for Evolving from Merely a Treatment for Complications to Targeting Diseases · 2016
    No notice
  126. 126.

    Barichella M Pacchetti C Bolliri C Cassani E Iorio L Pusani C. Probiotics and prebiotic fiber for constipation associated with Parkinson disease: an RCT. Neurology. (2016 ) 87:1274–80.

    Not in our library10.1212/wnl.0000000000003127

  127. 127.

    Wang H Lee I-S Braun C Enck P. Effect of probiotics on central nervous system functions in animals and humans: a systematic review. J Neurogastroenterol Motil. (2016 ) 22:589–605.

    Not in our library10.5056/jnm16018

  128. 128.
    Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson’s disease patients · 2017
    Corrected
  129. 129.

    Petrov VA Saltykova IV Zhukova IA Alifirova VM Zhukova NG Dorofeeva YB. Analysis of gut microbiota in patients with Parkinson's disease. Bull Exp Biol Med. (2017 ) 162:734–7.

    Not in our library10.1007/s10517-017-3700-7

  130. 130.
    Increased Intestinal Permeability Correlates with Sigmoid Mucosa alpha-Synuclein Staining and Endotoxin Exposure Markers in Early Parkinson's Disease · 2011
    No notice
  131. 131.

    Miraglia F Colla E. Microbiome, Parkinson's disease and molecular mimicry. Cells. (2019 ) 8:222.

    Not in our library10.3390/cells8030222

  132. 132.

    Taglialegna A Lasa I Valle J. Amyloid Structures as Biofilm Matrix Scaffolds. J Bacteriol. (2016 ) 198:2579–88.

    Not in our library10.1128/jb.00122-16

  133. 133.

    Van Gerven N Van der Verren SE Reiter DM Remaut H. The role of functional amyloids in bacterial virulence. J Mol Biol. (2018 ) 430:3657–84.

    Not in our library10.1016/j.jmb.2018.07.010

  134. 134.

    Tankou SK Regev K Healy BC Tjon E Laghi L Cox LM. A probiotic modulates the microbiome and immunity in multiple sclerosis. Ann Neurol. (2018 ) 83:1147–61.

    Not in our library10.1002/ana.25244

  135. 135.

    Söderling EM Marttinen AM Haukioja AL. Probiotic lactobacilli interfere with Streptococcus mutans biofilm formation in vitro. Curr Microbiol. (2011 ) 62:618–22.

    Not in our library10.1007/s00284-010-9752-9

  136. 136.

    Vuotto C Longo F Donelli G. Probiotics to counteract biofilm-associated infections: promising and conflicting data. Int J Oral Sci. (2014 ) 6:189–94.

    Not in our library10.1038/ijos.2014.52

  137. 137.

    Zmora N Zilberman-Schapira G Suez J Mor U Dori-Bachash M Bashiardes S. Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features. Cell. (2018 ) 174:1388–405.

    Not in our library10.1016/j.cell.2018.08.041

  138. 138.

    Singh B Mal G Marotta F. Designer probiotics: paving the way to living therapeutics. Trends Biotechnol. (2017 ) 35:679–82.

    Not in our library10.1016/j.tibtech.2017.04.001

  139. 139.

    Cohen PA. Probiotic safety—no guarantees. JAMA Intern Med. (2018 ) 178:1577–8.

    Not in our library10.1001/jamainternmed.2018.5403

  140. 140.

    Driver JA Logroscino G Gaziano JM Kurth T. Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology. (2009 ) 72:432–8.

    Not in our library10.1212/01.wnl.0000341769.50075.bb

  141. 141.

    Cooper JF Dues DJ Spielbauer KK Machiela E Senchuk MM Raamsdonk JMV. Delaying aging is neuroprotective in Parkinson's disease: a genetic analysis in C. elegans models NPJ Parkinson Dis. (2015 ) 1:15022.

    Not in our library10.1038/npjparkd.2015.22

  142. 142.

    Dethlefsen L Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci USA. (2011 ) 108 (Suppl. 1):4554–61.

    Not in our library10.1073/pnas.1000087107

Cited by papers we hold 3

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.